Ann: Qantas Group HY23 Appendix 4D and Interim Financial Report, page-30

First 30 Last

Share
Profile

Follow
canplan

416 Posts.

135

23/02/23

12:22

Post #: 66418714
Share

Originally posted by bedger ↑

Just remember John Maynard Keynes warning on solvency vs irrationality of the market.

I was short Tesla to the highs of around $410, warning on falling global mkt share of sales to Xpeng, BYD etc. The Twitter deal was a God send to me and I read the boring debt covenants at the SEC and then increased my shorts whilst the lemmings bought more of their deity and called me an idiot. I closed out my short at $108.

Too many people buy on headlines. Fundamentals always come back to roost. Joyce has blown a cool $billion and weakened the balance sheet on a share buyback that was badly needed money for Cap Ex. when airfares and the Qantas brand are falling quickly. This was a purple patch that Qantas sorely needed to shore up its business. Instead the Leprechaun blew on a buyback so he can exit his CEO position with plenty of moolah from his share awards....

Airfares still high says Joyce, yet bar this Saturday I can fly to the Gold Coast from Sydney for less than $100 any weekend I want. Melbourne? Oh, I have to pay $110 this Saturday and next, but otherwise the same. Those fares are near enough 2019 fares.

International flights have dropped significantly. I literally could not fly direct from London to Sydney in October last year, one way on a relatively direct flight for less then $2,500. I ended up flying crappy Air India and having a little holiday as it was cheaper. Direct London to Sydney flights now, even as short dated as March? $1,000 to $1,500.

The closest it provides to guidance is "Fares are expected to moderate during the second half as capacity increases but will remain significantly above FY 2019 levels."

Absolute rubbish. Airfares are already at 2019 levels. The cash printing time for QAN has passed.

Expand

these qantas threads are literally a meeting place for some of the world's worst shorter's to cry, discuss their epic failures and abuse others.

QAN Price at posting: $6.05 Sentiment: None Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

PL3

Patagonia looks to raise $2.15M for South American exploration and development

There are more pages in this discussion • 45 more messages in this thread...

First 30 Last

Add QAN (ASX) to my watchlist

(20min delay)
Last $6.12		Change 0.020(0.33%)		Mkt cap ! $9.972B

Open	High	Low	Value	Volume
$6.12	$6.15	$6.08	$14.00M	2.290M

Buyers (Bids)

No.	Vol.	Price($)
10	68170	$6.10

Sellers (Offers)

Price($)	Vol.	No.
$6.12	25980	3

View Market Depth

No.	Vol.	Price($)
8	53074	6.100
4	56924	6.090
3	12299	6.080
4	8191	6.070
2	3017	6.050

Price($)	Vol.	No.
6.120	400	1
6.130	57113	8
6.140	60457	13
6.150	121397	41
6.160	27694	4

Last trade - 16.10pm 09/07/2024 (20 minute delay)

QAN (ASX) Chart

Ann: Qantas Group HY23 Appendix 4D and Interim Financial Report, page-30

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Qantas Group HY23 Appendix 4D and Interim Financial Report, page-30

Top Stories

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News